Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

Overview of attention for article published in New England Journal of Medicine, March 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news: 81 news outlets
blogs: 2 blogs
policy: 1 policy source
twitter: 331 X users
patent: 1 patent
facebook: 1 Facebook page

wikipedia: 4 Wikipedia pages
reddit: 2 Redditors
video: 1 YouTube creator
guideline: 10 clinical guideline sources
podcasts: 3 podcasts

Readers on

mendeley: 400 Mendeley

So far, Altmetric has seen 382 X posts from 331 X users, with an upper bound of 4,740,657 followers.

NRG018, TC/DC+Pemの書類完成、院内申請へ。これからは体癌はICIが標準へ。こう言う書類作成が年末年始を跨ぐのは大変だが、遅滞なく患者さんに良い医療を届ける為、前進あるのみ。 https://t.co/ndFMuJEa4I

RT @NEJM: Late breaking at #SGOMtg: In patients with advanced or recurrent endometrial cancer, the addition of pembrolizumab to standard ch…

RT @DrChoueiri: In this phase 3 trial, the addition of #pembrolizumab to standard paclitaxel plus carboplatin chemotherapy in advanced #end…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 378 additional X posts.